Prevalence and risk factors for metabolic dysfunction-associated steatotic liver disease and fibrosis in recently diagnosed type 2 diabetes

doi:10.4254/wjh.123278

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 8

This Article

(3)

(4)

(0)

(39)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Hepatol. Aug 27, 2026; 18(8): 123278
Published online Aug 27, 2026. doi: 10.4254/wjh.123278

Prevalence and risk factors for metabolic dysfunction-associated steatotic liver disease and fibrosis in recently diagnosed type 2 diabetes

Astrid Ruiz-Margáin, Oscar Manuel Fierro-Angulo, José Alberto González-Regueiro, Sergio Cesar Hernández-Jiménez, Ana Cristina García-Ulloa, Victoria Landa-Anell, Fernando Bril, Berenice Montserrat Roman-Calleja, Regina Romo-Arellano, Ariana Pereira-García, Naga Chalasani, Ricardo Ulises Macías-Rodríguez

Astrid Ruiz-Margáin, Oscar Manuel Fierro-Angulo, José Alberto González-Regueiro, Berenice Montserrat Roman-Calleja, Regina Romo-Arellano, Ariana Pereira-García, Ricardo Ulises Macías-Rodríguez, Division of Hepatology and Liver Transplant, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico 14080, Ciudad de México, Mexico

Astrid Ruiz-Margáin, Ricardo Ulises Macías-Rodríguez, MICTLÁN-Network (Mechanisms of Liver Injury, Cell Death and Translational Nutrition in Liver Diseases Research Network), Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico 14080, Ciudad de México, Mexico

Astrid Ruiz-Margáin, Ricardo Ulises Macías-Rodríguez, Liver Fibrosis and Nutrition Lab (LFN Lab), Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico 14080, Ciudad de México, Mexico

Sergio Cesar Hernández-Jiménez, Ana Cristina García-Ulloa, Victoria Landa-Anell, Center of Comprehensive Care for the Patient with Diabetes, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico 14080, Ciudad de México, Mexico

Fernando Bril, Endocrinology, Diabetes & Metabolism, University of Alabama at Birmingham, Birmingham, AL 35233, United States

Naga Chalasani, Department of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, IN 46202, United States

Co-first authors: Astrid Ruiz-Margáin and Oscar Manuel Fierro-Angulo.

Author contributions: Macías-Rodríguez RU, Ruiz-Margáin A designed the study; Macías-Rodríguez RU acquired funding; Macías-Rodríguez RU, Ruiz-Margáin A drafted the initial protocol; Macías-Rodríguez RU, Fierro-Angulo OM, González-Regueiro JA collected data; Ruiz-Margáin A performed the statistical analysis; Macías-Rodríguez RU, Fierro-Angulo OM, Ruiz-Margáin A, González-Regueiro JA, Hernández-Jiménez SC, García-Ulloa AC, Landa-Anell V, Roman-Calleja BM, Romo-Arellano R, Pereira-García A drafted and reviewed the manuscript; Bril F, Chalasani N critically reviewed the manuscript; all authors contributed to the study and approved the final version of the manuscript. Ruiz-Margáin A and Fierro-Angulo OM contributed equally to this work as co-first authors.

AI contribution statement: No AI was used in this manuscript.

Institutional review board statement: This is a cross-sectional study carried out at a tertiary hospital in Mexico City from January 2022 to January 2024. The study followed the principles outlined in the Declaration of Helsinki and was approved by the Research Ethics Committee of the institution (Ref. No. 2985).

Informed consent statement: All participants at the center of comprehensive care for the patient with diabetes clinic provided informed written consent for the evaluations included in this study.

Conflict-of-interest statement: The authors declare no conflicts of interest for this study.

STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.

Data sharing statement: The data that support the findings of this study are available from the corresponding author upon reasonable request.

Corresponding author: Ricardo Ulises Macías-Rodríguez, MD, PhD, Professor, Research Assistant Professor, Division of Hepatology and Liver Transplant, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Av. Vasco de Quiroga 15, Col. Belisario Dominguez Secc. XVI, Mexico 14080, Ciudad de México, Mexico. ricardo.maciasr@incmnsz.mx

Received: May 13, 2026
Revised: June 26, 2026
Accepted: July 30, 2026
Published online: August 27, 2026
Processing time: 97 Days and 9.1 Hours

Core Tip

Core Tip: There is scarce data specifically evaluating the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) and liver fibrosis in patients with recent-onset type 2 diabetes (< 5 years since diagnosis) and without micro or macrovascular complications. The Hispanic population is regarded as high-risk for metabolic diseases, including MASLD. We found a high prevalence of MASLD, affecting 41.4% of the study population, with 10% presenting clinically significant liver fibrosis (liver stiffness measurement ≥ 8 kPa) and 3% having cirrhosis. Our findings support incorporating liver health screening into the routine evaluation of patients with type 2 diabetes mellitus from diagnosis, even in those with good glycemic control and without chronic complications.